🟢 Arcturus Therapeutics is trading 10.6% up today after renewed coverage of regained global KOSTAIVE rights

Arcturus Therapeutics is trading 10.6% up at $12.15 after renewed coverage of its regained global KOSTAIVE rights and broader infectious-disease vaccine portfolio.

• The CSL Seqirus settlement included a $12 million cash payment and approximately $16 million in liability relief, strengthening strategic control and the balance sheet.
• Shares rose 25.21% on August 19 and 6.91% on August 20 as the catalyst gained attention.
• The move comes despite biotech sector weakness; trading activity is elevated, with momentum continuing into the August 21 session.